).
• Conclusion: The explicit recognition of MLC was strongly associated with improvements in appropriate waiting list registration for LT.
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T he survival benefit associated with liver transplantation (LT) is superior to any medical therapy for the management of complications associated with end-stage liver disease (ESLD). As a result, the number of patients referred and registered for LT has increased. However, in the United States, the discrepancy between donor organ availability and recipient need has increased, despite appropriate increases in organ donation. 1 Therefore, registration of patients without ESLD for LT raised concerns about "waiting list inflation" and perceived inequities with the organ allocation system. 1, 2 To address these concerns, the recognition of minimal listing criteria (MLC) for waiting list registration was endorsed by the United Network for Organ Sharing (UNOS).
3
A Child-Turcotte-Pugh (CTP) score of 7 or higher, indicative of an estimated 1-year survival rate lower than 90%, was selected as the basis for MLC. The CTP score is a modification of an existing scale, 4 which includes a variation developed for cholestatic liver disease. Five variables-hepatic encephalopathy, ascites, total bilirubin, albumin, and prothrombin time-are each assigned a numerical value from 1 to 3 that signifies the clinical severity of each variable. 5 Patients with compensated cirrhosis or a CTP score lower than 7 would be ineligible for waiting list registration unless they received regional board approval. 3 The formal recognition of MLC was intended to establish uniformity in selecting eligible patients for LT waiting list registration while preserving this aspect of equity in the organ allocation system. However, to date, little information has assessed the results of formal MLC recognition on outcomes associated with the LT waiting list registration process. Specifically, we sought to determine whether the explicit use of MLC was associated with significant improvements in appropriate waiting list registration of eligible patients compared with previous selection practices.
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In addition, we examined the association between MLC recognition and patterns of patient referral to our center.
PATIENTS AND METHODS
The study population consisted of patients older than 18 years referred to the Mayo Clinic in Rochester, Minn, for LT evaluation. To facilitate a comparison between outcomes before and after formal MLC implementation by UNOS, 2 distinct cohorts were identified. Cohort A consisted of patients referred between January 1, 1997, and November 30, 1997, when MLC was not explicitly used for determining LT waiting list registration. Cohort B consisted of patients referred between December 1, 1997, and December 31, 1998; formal recognition of MLC occurred after December 1, 1997. In total, 219 patients from cohort A and 250 patients from cohort B were identified as referrals for LT evaluation and possible waiting list registration. Patients with a prior history of LT, previous LT evaluation at the Mayo Clinic in Rochester before January 1, 1997, or a previous evaluation for LT at another center (including centers within the Mayo Foundation) were excluded from analysis. Thus, 147 patients from cohort A and 201 patients from cohort B with ESLD who were referred for an initial LT evaluation were considered eligible for the study.
Data Collection
We identified patients by using a prospective database compiled by the institution's LT program for tracking all patients who undergo formal consideration for waiting list registration. It captures the demographic and clinical data required by UNOS to register acceptable candidates formally. This concise database does not include all patients who may have been referred for consideration of LT. Reasons for this include patient refusal of potential LT, identification of individuals with absolute contraindications before formal presentation, or third-party payer restrictions for a consultative evaluation only. Data abstraction from this source and individual medical records when necessary was performed after Mayo Foundation Institutional Review Board approval and patient consent. Variables of interest to the waiting list registration process included patient age, sex, race, blood type, residency status (US or foreign national), hepatic disease etiology, UNOS region of referral (if applicable), and waiting list registration status (accepted or denied). Information on medical history, physical examination, and laboratory, radiographic, endoscopic, and histological data relevant for the assessment of ESLD was also recorded. Complications of portal hypertension were identified and defined as follows: (1) esophageal and/or gastric variceal bleeding confirmed by history and diagnostic endoscopy; (2) ascites defined by clinical and/or radiological findings in the presence or absence of oral diuretic therapy; (3) portosystemic encephalopathy defined by appropriate clinical findings or symptom improvement with medical therapy consisting of lactulose and/or neomycin; (4) spontaneous bacterial peritonitis (SBP) defined by clinical history and ascitic fluid studies including a polymorphonuclear cell count of 250/mm 3 or higher and/or positive bacterial cultures; and (5) hepatorenal syndrome (HRS) defined by accepted criteria. 6 
Demographic and Clinical Features
We examined differences in relevant demographic and clinical features between eligible patients in cohorts A and B, including overall waiting list registration rates. In addition to a CTP score of 7 or higher as the basis for MLC, a history of serious complications of portal hypertension, including refractory variceal bleeding and SBP, was also recognized as sufficient for MLC. First-time patient referral rates for LT evaluation before and after MLC recognition were also compared. The proportion of registered patients with CTP scores of 7 or higher in each cohort was compared to determine the level of significance associated with MLC implementation. In cohort A, the calculation of CTP scores for each patient with use of information recorded at the time of LT evaluation facilitated this comparison. Because MLC were not formally recognized during the period represented by cohort A, clinical factors associated with waiting list registration for these patients were also determined. The prevalence rate of advanced ESLD between cohorts was compared. Advanced ESLD was defined by a CTP score of 10 or higher or a CTP score of 7 or higher with any of the following: refractory variceal bleeding requiring 2 U or more of packed red blood cells, refractory ascites requiring serial paracentesis of 4 L or more within 14 days despite medical therapy, hepatic hydrothorax refractory to medical therapy, HRS, and/or SBP.
Statistical Analyses
Continuous data were expressed as mean ± SE or median when appropriate. Categorical data were expressed as the number of patients (or proportion) with a specified condition or clinical variable. The detection of significant differences between continuous variables by cohort was performed by using the nonparametric Wilcoxon rank sum test. Comparisons of frequency data for significant differences were performed by using the χ 2 or Fisher exact test, when appropriate. Univariate analysis was performed to determine the association between relevant clinical predictors and waiting list registration in cohort A. Variables of potential significance (P≤.20) were then examined by multivariate stepwise logistic regression analysis to identify independent predictors of registration. P≤.05 was statistically significant for all analyses.
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Among patients with first-time LT evaluations in cohort B with a CTP score of 7 or higher, 135 (96%) of 140 patients were registered on the waiting list. In contrast, 79 (82%) of 96 patients from cohort A with CTP scores of 7 or higher were registered. The improvement in registration rate between cohorts A and B was statistically significant (P=.001).
Univariate analysis identified patient age, male sex, CTP score of 7 or higher, and hepatic disease due to primary biliary cirrhosis or chronic hepatitis C as potential factors influencing waiting list registration in patients in cohort A. Hepatic disease due to alcohol was found to be negatively associated with waiting list registration ( Table  2) . Multivariate logistic regression analysis identified patient age, male sex, nonalcohol-related hepatic disease, and CTP score of 7 or higher as independent predictors of waiting list registration after controlling for the effects from confounding variables ( Table 3) . Of note, only 7 (8%) of 86 patients from cohort A who were denied waiting list registration were found to have CTP scores of 7 or higher. None of these patients was denied waiting list registration based on absolute or relative contraindications, including advanced age, severe comorbid illness, and active untreated alcoholism.
DISCUSSION
To our knowledge, this is the first investigation that has systematically examined the effect of recognizing MLC as a process measure on the outcome of waiting list registra- tion for LT. By examining similar patient cohorts before and after MLC implementation, a significant 14% improvement in appropriate registration of patients with CTP scores of 7 or higher was observed. Only 8% of patients in cohort A who were not registered for LT (each with CTP score of 7) would have benefited from the explicit use of MLC. In addition, an 11% increase in first-time patient referrals after MLC recognition was observed despite similar demographic and clinical characteristics between cohorts. Although the proportion of patients with CTP scores of 10 or higher in each cohort remained similar, the total number of first-time referred patients with advanced ESLD increased after MLC recognition. The Child-Turcotte classification system was initially developed for assessing outcomes among cirrhotic patients after decompressive shunt surgery. 4 Despite the eventual
For personal use. Mass reproduce only with permission from Mayo Clinic Proceedings. transformation of the Child-Turcotte classification to the CTP classification (nutritional status was substituted by prothrombin time), 5 several limitations remained for its use as an accurate prognostic index. These include subjective assessments for degree of involvement with ascites and hepatic encephalopathy and the inability to describe a spectrum of disease severity. 7, 8 However, the CTP score continues to be widely used by clinicians and researchers for discriminating between compensated and decompensated cirrhosis. Because of its simplicity and practicality, the CTP score was ultimately recognized by UNOS as the method of choice for determining eligibility for LT waiting list registration in 1997. 3 With a greater awareness of the successes associated with LT, an increasing number of patients identified with ESLD have been referred for this procedure. 9 Previous concerns about waiting list inflation because of registration of patients with compensated cirrhosis prompted the development of MLC. 3 The increase in UNOS waiting list registrations from 2303 (1992) to 9647 (1997) was proposed to reflect this situation. However, this observation may not be entirely based on curtailment of the practice of registering patients with compensated cirrhosis. Evidence from our medical center suggests that a CTP score of 7 or higher was being implicitly used 8 (referred to as "the gestalt method" by Conn 7 ) in most patients approved for waiting list registration in 1997 (cohort A). In addition, patients with advancing ESLD who had a CTP score of 10 or higher may continue to be registered at UNOS status 3 until urgent indications for LT occur. Although registration of stable patients ineligible for LT may have been prevented, a continued increase was observed in UNOS waiting list census (up to 14,709 by 1999) 10 after MLC implementation. In our study, there was no significant increase in the proportion of patients with advanced ESLD defined primarily by a CTP score of 10 or higher. However, a numerical increase in first-time referrals with advanced ESLD was associated with the formal recognition of MLC. No significant increase in the frequency of complications due to portal hypertension among cohort B patients was observed to explain this finding. Although coinciding with MLC implementation, the decision to refer patients for consideration of LT is admittedly multifactorial and based on both patient and physician factors. However, an increase in patient referrals from providers in our own institution was stimulated by the formal recognition of MLC.
The significant negative association between waiting list registration for LT and alcoholic liver disease before MLC implementation appears consistent with expectations from the organ allocation system. The influence of professional and public preferences for strict adherence in offering LT to selected individuals with alcoholic liver disease remains consistent. [11] [12] [13] Discrimination against persons engaging in socially undesirable behaviors (such as active alcohol dependence) is consistently cited among public inquiries 12 despite contesting arguments weighted by ethical analysis. 13 While it is likely that individuals with alcoholic liver disease who may be appropriate candidates for LT are not referred based on physician attitudes, the scope of the current investigation could not address this issue.
To assess the effect of MLC recognition as a process measure for consistent LT waiting list registration, several issues were raised. The identification of our program's adherence to MLC recognition should not be considered self-fulfilling. Although not traditionally considered a formal indicator of quality health care, the ability to demonstrate compliance with MLC implementation ensures that no important variations exist in waiting list selection practices. The increase in first-time patient referrals in cohort B could not be explained by a greater prevalence of ESLD due to chronic hepatitis C or significant improvements in survival after MLC recognition.
Factors that strongly influence patient referral patterns independent of hepatic disease severity include access to an LT center 14 and physician attitude about LT. However, these reasons could not be formally tested in our study because they are related to processes outside the LT center. Poor socioeconomic status and reduced education level are infrequently cited as reasons to deny waiting list registration, provided their level of severity is not detrimental in optimizing long-term outcomes from LT. 15 The accuracy in determining ESLD severity by using a recalculated CTP score among cohort A was also likely affected by the subjective nature for grading ascites and portosystemic encephalopathy. However, these limitations have also been documented in clinical practice. 2 Outcomes including LTrelated and waiting list mortality rate, although important for determining the overall effectiveness of organ allocation systems, were not addressed because of the specific process-outcome relationship that we examined.
Because of concerns that the waiting time for LT was determining organ allocation instead of medical severity of illness, 16 recent discussions have focused on maximizing outcomes after LT while maintaining fairness and equity in the system. As a result, the CTP score was declared to be an insufficient method for determining the need for urgent LT. 17 Using a prognostic index initially developed to predict 3-month mortality risk among patients referred for transjugular intrahepatic portosystemic shunt placement, 18 Kamath et al 19 showed that the model for end-stage liver disease (MELD) was also highly predictive of mortality risk among various ESLD patient populations. The clinical variables for this model include serum bilirubin, prothrombin time measured by the international normalized ratio, and serum creatinine. Accuracy in survival estimates from the MELD are not significantly affected by complications related to portal hypertension or hepatic disease etiology. Compared to the CTP score, the MELD score describes a continuum of disease severity and uses objective, readily available clinical data. After consideration by UNOS and the US Department of Health and Human Services, the MELD score was approved to replace the CTP score for determining LT organ allocation in the United States beginning in February 2002.
In conjunction with identifying methods to ensure optimal timing of LT, appropriate identification of patients who may eventually require LT remains important. Despite objective improvements in assessing disease severity with the MELD score, the referral of ESLD patients to LT centers should continue to be guided by MLC. In conjunction with community-based providers, a schedule of periodic follow-up and recalculation of the MELD score with current data can then be facilitated to ensure optimal timing of LT when indicated. However, the challenge of creating allocation guidelines that reflect acceptable professional and community preferences will continue to remain dynamic as the field of LT continues to evolve.
